🌍·1d agodiscovery
MoonLake’s Sonelokimab Achieves 67% HiSCR75 Response in Phase 3 HS Trial
Publisher
T
The Clinical Trial Vanguard
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Clinical Trial Vanguard
- Region
- Global
- Scope
- discovery
- Published
- June 22, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Clinical Trial Vanguard
Scope: discovery
Related coverage
More related coverage
Pulse 2.0/3h ago
Evonik Sells Hanau Pharmaceutical Ingredients Production Assets To ProChem
Bloomberg Law News/4h ago
Biotech Chief Says Industry in ‘Better Place’ After FDA Changes
China Daily/5h ago
Innovent-Pfizer deal makes joint development, commercialization pillar in biotech global push
The Motley Fool/5h ago